Trial
NCT02626455
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Bayer
Collaborators
—
Condition
Lymphoma, Non-Hodgkin
Intervention
Copanlisib (BAY80-6946)
Why stopped
Company decided to terminate this study due to study did not meet the primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-11